IL138647A - Synthesis of compounds and libraries of compounds - Google Patents

Synthesis of compounds and libraries of compounds

Info

Publication number
IL138647A
IL138647A IL138647A IL13864700A IL138647A IL 138647 A IL138647 A IL 138647A IL 138647 A IL138647 A IL 138647A IL 13864700 A IL13864700 A IL 13864700A IL 138647 A IL138647 A IL 138647A
Authority
IL
Israel
Prior art keywords
peptide
reaction
group
functionalized
unfunctionalized
Prior art date
Application number
IL138647A
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IL138647A publication Critical patent/IL138647A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Description

Synthesis of compounds and libraries of compounds President and Fellows of Harvard College C. 128229 SYNTHESIS OF COMPOUNDS AND LIBRARIES OF COMPOUNDS Priority Information This application claims priority to the provisional application, 60/079,035, entitled "Synthesis of Compounds with Peptide Characteristics", filed March 23 , 1998, the entire contents of which are incorporated herein by reference.
Background of the Invention The important biological roles that peptides plaz as hormones, enzyme inhibitors, substrates, neurotransmitters, and neuromediators has led to the widespread use of peptides in medicinal chemistry as therapeutic agents. Through binding to receptors or enzymes, peptides are able to influence cell-cell communication and control vital cell functions such as metabolism, immune defense and reproduction. (Babine et al., Cham. Rev. 1997, 9 ~, 1359) Unfortunately, the utility of peptides as drugs is severely limited by several factors, including their rapid degradation by peptidases under physiological conditions, their poor cell permeability, and their lack of binding specificity resulting from conformational flexibility.
In response to these unfavorable characteristics of peptide drugs, many research groups have developed strategies for the design and synthesis of chemical compounds, known as "peptidomimetics", in which sensitive peptide moieties are removed and replaced with more robust functionalities. In particular, researchers have sought to improve peptide stability and cell permeability by replacing the amide functionality with groups such as hydroxyethylene, (E)-alkenes, carba groups and phosphonamide groups (Gante, J., Angew. Che . Int. Ed. Engl. 1994, 33, 1699- 1720, and references cited therein).
In most cases, these peptidomimetic compounds have been prepared one at a time.
A few researchers have also attempted to design combinatorial strategies to produce peptidomimetic libraries (Boger, D, WO 96/03424; Ellman, J., U.S. Patent No. 5,545,568; Simon, R. et al., Proc. Natl. Acad Sci. USA 1992, 89, 9367, Bartlett et al., Proc. Natl. Acad Sci. USA 1992, 89, 9367). Unfortunately, these efforts are often limited by lack of 138647/2 WO 99/48897 PCTAJS99/06233 stereochemical complexity and control, and/or by restricted ability to substitute base molecules. Also, existing peptidomimetic strategies generally rely on a fixed structure to mimic che peptide bond, and do not allow subsequent modification and diversification of this structure.
There remains a need to develop a synthetic strategy capable of producing complex, highly diversified libraries of compounds that can act as peptidomimetics. There is a particular need for methods and compounds that allow significant stereochemical control . and functional group diversity in the production of such libraries. Furthermore, because of the importance of stereochemical complexity in the synthesis of these and other libraries, there also remains a need for the development of stereodiverse compounds and libraries of compounds.
Summary of the invention The present invention provides a method for generating a library of compounds having stereochemical diversity. The method comprises: selecting desired synthetic precursors having a defined stereochemical relationship; reacting the synthetic precursors under olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction conditions to yield one or more compounds having specific stereochemistry; repeating the steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained.
The desired selection of desired synthetic precursors comprises selecting two monomerseach independently selected from a specific compound having the general structure: wherein Ln and Li2 are each independently selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated 138647/2 WO 99/48897 PCT/US99/06233 aromatic, aldehyde, vinyl halide, HR1; SRi, ORi, wherein each occurrence of Ri is independently selected from the group consisting of protected or unprotected, functionalized or unfunctionalized amino acid, functionalized or unfunctionalized peptide, functionalized or unfunctionalized peptide fragment, solid support unit, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit) and (functionalized or unfunctionalized peptide fragment-solid support unit); wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; wherein R is selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, Ci-C4 alkyl, aryl, phenoxy, methoxy, halide, Sme, cycloalkyl, (CH2)-cycloalkyl, benzyl, arloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; and wherein X] comprises a moiety selected from the group consisting of hydrogen, hydroxy, protected hydroxy, thiol, protected thiol, N3, amino, protected amino, alkylamino and dialkylamino, whereby each of said monomers may comprise the same or different specific compound; and wherein the step of reacting the synthetic precursors comprises linking said same or different monomers using a linking reagent and subsequently reacting said monomers intramolecularly.
The invention is further directed to a method for preparing a morphed peptide derivative. The method comprises the steps of: identifying an active peptide sequence; replacing at least one di- or tri-peptide unit, or at least one of both, with a non-peptide morphed unit synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and identifying a peptide derivative that retains at least part of the active sequence activity.
The invention is also directed to a method for preparing a library of morphed peptide derivatives. The method comprises the steps of: identifying one or more biologically active peptide sequences; replacing, in said one or more active peptide sequences, at least one di- or tri-peptide unit, or both, with a non-peptide unit synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and 138647/2 O 99/48897 PCT/US99/06233 screening the peptide derivative library to identify one or more peptide derivatives within it that retain at least part of the active sequence activity.
The invention is yet further directed to a method for morphing a peptide into a non-peptide compound. The method comprises the steps of: identifying a biologically active peptide sequence; preparing a library of morphed peptides in which each peptide has the active sequence except that at least one di- or tri-peptide unit, or both, has been substituted with a library of non-peptide morphed units synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and screening the peptide derivative library to identify one or more peptide derivatives within it that retain at least part of the active sequence's activity.
The method may further comprise: preparing a second library of morphed peptide derivatives, the second library being produced from the first identified peptide derivative by substituting at least a second di- or tri-peptide moiety within the first derivative with a library of non-peptide morphed units; and screening the second peptide derivative library to identify one or more second peptide derivatives that retain at least part of the active sequence's activity.
The library of non-peptide morphed units substituted into a di-peptide or tri-peptide unit, or both, of the active peptide sequence comprises the structure: wherein Ri and R2 are each independently selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, C1-C4 alkyl, aryl, phenoxy, methoxy, halide, Sme, cycloalkyl, (CH2)-cycloalkyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; wherein A is absent, whereby -C(X2) form a covalent bond, or wherein A is selected from the group consisting of: alkane; -(CH2)n-(CH=CH)-, where n = 0 or 1 ; aryl; substituted aryl; heterocycle; substituted heterocycle; cycloalkane; substituted cycloalkane; and alkyne; wherein Xi and X2 are each independently selected from the group consisting of hydrogen, hydroxy, protected hydroxy, thiol, protected thiol, N3 amino, protected amino, alkylamino, and dialkylamino; and wherein (Ln-X3) and (X -L22) each taken together are each independently selected from the group consisting of: -NHR4; -CH2-NHR4; -COOR ; -CH2OR4; -COSRY4; -CO-NH-R4; -NH-CO-R4 wherein each occurrence of R4, as valency and stability permit, is independently selected from the group consisting of hydrogen, hydroxy, alkyl, protecting group, solid support unit, functionalized or unfunctionalized, protected or unprotected peptide or fragment thereof, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit), and (functionalized or unfunctionalized peptide fragment-solid support unit); and [R2 and (X4-LH)] or [Rj and (X3-L1 1)] taken together each independently comprise a protecting group, or a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocyclic moiety. 4b 138647/1 Description of the Drawing Figure 1 depicts the Peptide Morphing strategy of the present invention.
Figure 2 depicts a retrosynthetic analysis of a preferred structure of the present invention.
Figure 3 depicts cenain preferred monomers having a syn relationship between the allylic alcohol and the functional group.
Figure 4 depicts bond construction through palladium coupling.
Figure 5 depicts bond construction through pinacol coupling.
Figure 6 depicts bond construction through tandem aldol reaction followed by Curtius rearrangement.
Figure 7 depicts hydrozirconation reactions.
Figure 8 depicts a nucleophilic addition reaction.
Figure 9 depicts Nozaki-Hiyama- ishi coupling reactions.
Figure 10 depicts attachment of a morphed segment to the resin.
Figure 1 1 depicts synthesis of the C-terminal (first) monomer.
Figure 12 depicts the synthesis of the N-terminal (second) monomer.
Figure 13 depicts a convergent and efficient synthesis of monomers.
Figure 14 depicts Hoffman, Lossen and Schmidt Rearrangements.
Figure 1 5 depicts intramolecular olefin metathesis.
Figure 16 depicts reaction of a dimethyldichlorosilane linker with preferred monomers of the invention.
Figure 17 depicts reaction of a diisopropyl amino chlorophosphoramidite linker with preferred monomers of the invention.
Figure 18 depicts Figure ! 9 depicts cross metathesis.
Figure 20 depicts Figure 21 depicts Figure 22 depicts Figure 23 depicts Figure 24 depicts Figure 25 depicts Figure 26 depicts domain.
Figure 27 depicts Figure 28 depicts Figure 29 depicts the E6 E6-AP system.
Figure 30 depicts a use for the compounds and libraries of the present invention in the renin-angiotensin system.
Figure 3 1 depicts a use for the compounds and the libraries of the present invention as inhibitors of the proteasome.
Figure 32 depicts the synthesis of compound 2.
Figure 33 depicts the synthesis of compound 3.
Figure 34 depicts the synthesis of compound 4.
Figure 35 depicts the synthesis of compound 5.
Figure 36 depicts the synthesis of compound 6.
Figure 37 depicts the synthesis of compound 7.
Figure 38 depicts the synthesis of compound 8.
Figure 39 depicts the synthesis of compound 9.
Figure 40 depicts the synthesis of compound 10.
Figure 41 depicts the synthesis of compound 1 1 .
Figure 42 depicts the synthesis of compound 12.
Figure 43 depicts the synthesis of compound 13.
Figure 44 depicts the synthesis of compound 14 Figure 45 depicts the synthesis of compound 15.
Figure 46 depicts the synthesis of compound 16.
Figure 47 depicts the synthesis of compound 17.
Figure 48 depicts the synthesis of compound 18.
Figure 49 depicts the synthesis of compound 19.
Definitions "'Peptidomimetic": The term "peptidomimetic", as used herein, refers to a chemical compound that, at least in part, mimics one or more structural or functional properties of a peptide. As discussed above, the prior art definition of peptidomimetic focuses on 6 compounds in which one or more of the characteristic chemical moieties of a peptide is substituted with alternative functional groups. The present invention provides a broader concept of peptidomimetic, describing a system for producing a wide variety of chemical compounds that may have one or more structural or functional aspects of biologically active peptides. That is, for the purposes of the present invention., a peptidomimetic does not necessarily refer to a compound that per se imitates the properties of a peptide, but can also refer to a compound in which a segment unit replacement of the amide functionality, which bears no structural relationship to a peptide functionality, is capable of interacting with a biological receptor or ligand with desired specificity. To give but a few specific examples, peptidomimetics include, but are not limited to, compounds in which the amide bond of a peptide is replaced with alkene, hydroxyethylene or carba functionalities. Peptidomimetics also include compounds in which the cc-CH group is replaced with aza, C-alkyl, or bora functionalities, among others.
"Combinatorial Library" : The term "combinatorial library", as used herein, refers to a collection of compounds produced in a manner that allows "segment units", 'functionality units", "monomer units", "biomolecule units", or any combination thereof, to be varied in a systematic fashion. The segment unit may be generated from any compatible reaction between monomers (or upon a monomer) that results in a replacement of the amide functionality with any other functionality. The functionality units may be varied on individual monomers, or after monomers have been joined together. These functionality units may be present within the segment unit of the joined monomers, or may be present at other sites within the monomers.
"Biomolecules": The term "biomolecules", as used herein, refers to molecules (e.g., proteins, amino acids, nucleic acids, nucleotides, carbohydrates, sugars, lipids, etc.) that are found in living cells in nature.
"Monomer unit" . The term "monomer unit", as used herein, refers in one aspect to a molecule that can be joined together to form another molecule or set of molecules, such as a set of oligomers or polymers. In another aspect "monomer unit", as used herein, refers to a molecule that can be diversified at particular sites on the monomer unit. More particularly, the present invention refers to a monomer that is characterized in that it 7 contains reactive moieties available for diversification and optionally is characterized by the presence of a reactive moiety that allows linkage of multiple individual monomers by way of a segment unit functionality.
"Diversity element": The term "diversity element", as used herein, refers to structural (i.e., functional group diversity), stereochemical, diastereochemical, and/or regiochemical diversity in a particular compound. As will be appreciated by one of ordinary skill in the art, the present invention provides for the synthesis of compounds and libraries of compounds having any of these diversity elements alone or in combination with one or more of the other diversity elements.
"Stereoisomer": The term "stereoisomer", as used herein, refers to a structure of the same constitution as another structure, differing only in the spatial arrangement.
Stereoisomers are described by specifying their topology and the nature of their relationship to other stereoisomers of the same constitution.
"Enantiomer": The term "enamiomer", as used herein, refers to a stereoisomer that is related to another stereoisomer as an object and its mirror image.
"Diastereomer": The term "diastereomer", as used herein, refers to a stereoisomer that is related to another stereoisomer in a manner other than as an object and its mirror image. For example, one stereogenic center relative to another stereogenic center is different for diastereomers. Diastereomers differ from one another both in physical properties and in chemical reactivities. For example,- different diasteriomers generally have different melting points, boiling points, and solubility characteristics.
"Stereoselective Reaction": The term "stereoselective reaction" refers to a chemical reaction in which one of the stereoisomeric products is formed in excess.
"Enantioselective Reaction": The term "enantioselective reaction" refers to a chemical reaction in which one of the enantiomeric products is formed in excess.
"Diastereoselective Reaction": The term "diastereoselective reaction" refers to a reaction in which only one of the diastereomeric products is formed in excess, or one in which the major product is diastereomerically pure.
"Regioselective Reaction": The term "regioselective reaction" refers to a reaction in 8 SUBSTITUTE SHEET Detailed Description of Certain Preferred Embodiments As discussed above, the present invention provides methods and compounds related to production of complex libraries of chemical compounds with certain structural and/or functional characteristics of peptides. In addition to providing compounds and libraries of peptide-like compounds and methods for their syntheses, the present invention, in a broader aspect, provides for the generation of chemical libraries of peptidomimetics and non-peptidomimetics alike, having stereoisomerism as a diversity element.
In one particularly preferred embodiment, as shown in Figure 1 , the inventive reactions involve steps of ( 1 ) providing at Jeast two monomer compounds, each of which has at least two terminal reactive moieties; and (2) reacting the monomers with one another, under conditions that allow for the control of stereochemistry as well as chemoselectivity, so that they become linked together at one of their reactive moieties and generate a segment unit, and (3) generating diversifiable isolable compounds or libraries of compounds.
Typically, each monomer contains multiple reactive moieties, and additional reactions are performed to functionalize these moieties either before or after the monomers are linked to one another, so that highly complex libraries are produced.
In another particularly preferred embodiment; the inventive reactions involve steps of ( I ) providing at least one monomer compound, which has at least two terminal reactive moieties; (2) reacting the monomer with a reagent that allows for the control of stereochemistry as well as chemoselectivity, and (3) generating diversifiable isolable compounds or libraries of compounds with characteristics reminiscent of peptides.
One advantage of the inventive synthetic system is that it allows simultaneous production of a large number of complex peptidomimetic compounds under conditions of controlled stereo- and regio-selectivity. Preferred peptidomimetic compounds produced according to the present invention contain both peptide bond and functional group substitutions when compared with peptides. Thus, the present invention represents a 9 broadening of the conception of peptidomimetics. In fact, another advantage of the present system is that these substitutions are not necessarily limited to compounds that represent structural mimics of peptides, as might be found in the prior art. Instead, the inventive system, through a segment unit replacement, enables the maximization of the diversification of structures. The invention therefore enables the discovery of heretofore unanticipated interactions of compounds, that bear little or no structural relation with peptides, with biological receptors or ligands.
As will be appreciated by one of ordinary skill in the art, the method of the present invention and the ability to control the specific stereochemistry has a broader context than the immediate application to peptidomimetics. Rather, the present invention also provides for the generation of libraries having stereodiversity. Thus, in another aspect, the present invention provides methods for the generation of compounds and libraries of compounds, peptidomimetics and non-peptidomimetics alike, having stereochemical diversity. This method involves the steps of (1 ) selecting desired synthetic precursors having a predefined stereochemical relationship; (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained; and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained. In preferred embodiments, a library of compounds having only diversity of stereochemistry is provided. For these embodiments, it is particularly preferred that at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided. In other preferred embodiments, a library of compounds having structural diversity and stereochemical diversity is provided. Thus, for each compound having a specific structural formula, it is particularly preferred that for each structure at least 4 stereoisomers are provided, more particularly preferred that at least 8 stereoisomers are provided, and most particularly preferred that at least 16 stereoisomers are provided.
Various characteristics of the monomers and reactions utilized in preferred embodiments of the present invention are discussed in more detail below; certain examples of inventive reactions and compounds are also presented.
Monomers As mentioned above, preferred embodiments of the invention utilize either a single monomer or at least two monomers. Figure 2 depicts the retrosynthetic analysis of a preferred diversifiable peptidomimetic core, in which two monomers are used to generate the desired structure. Each monomer is characterized either by the presence of a reactive moiety that facilitates the linkage of the monomers to one another by way of a segment unit, or by the presence of a reactive moiety that facilitates the reaction of the monomers with chemical reagents. Each monomer preferably also contains additional reactive moieties available for diversification, so that the peptidomimetic compounds produced according to the present invention can be diversified bo at the level of the segment unit structure and at the level of functional groups. Preferably, each monomer contains at least one terminal reactive moiety that allows the monomer to be linked to a biomolecule. In particularly preferred embodiments, each monomer contains a moiety available for linkage to a peptide, so that the inventive peptidomimetic compounds can readily be embedded within a peptide chain.
The monomers utilized in accordance with the present invention are selected to allow for significant control of the stereo- and regio-chemistry of the reactions that they undergo. Furthermore, as will be appreciated by those of ordinary skill in the art, and is discussed in more detail below, in embodiments utilizing at least two monomers, each monomer is selected to react with the other monomer being employed. Thus, the chemical nature of the moiety on the first monomer that is available for linkage to the second monomer places constraints on the nature of the acceptable second monomer moiety and therefore limits the selection of the second monomer, and also limits the resulting stereoselectivity.
In certain preferred embodiments of the invention, at least one monomer contains a reactive moiety available for linkage to the solid phase. Such linkage may be direct or indirect. For example, the monomer may be linked to another molecule, preferably a biomolecule (and most preferably a peptide) that is itself linked to the solid phase.
Methods of linking compounds to the solid phase are known in the art and a variety of methods may be employed in the present invention. (See, for example, Brown, "Recent 1 1 Developments in Solid-Phase Organic Synthesis" Contemporary Organic Synthesis, 1997, p. 216; Hiroshige et al., Tet. Lett. 1995, 36, 4567; Rotella, D., J. Am. Chem. Soc. 1996, 118, 12246 and references cited therein.) The monomers utilized in the present invention are preferably easily synthesized, in high yields with High diastereo- and enantioselectivity. Examples of certain preferred monomers having a syn relationship between the allylic alcohol and the functional (R) group are depicted in Figure 3. In addition to providing monomers having a syn relationship, the present invention provides monomers having an anti relationship as depicted in Examples 13-29. Thus, the ability to provide monomers having ali possible stereoisomers enables the synthesis of compounds and libraries of compounds having significant stereodiversity.
Scheme 1 below, depicts a general scheme of a particularly preferred embodiment of the present invention for the synthesis of inventive compounds and libraries of compounds: Monomer I Monomer 2 Scheme 1 12 As depicted, each monomer contains first (L, , and L2]) and second (L12 and Lr terminal functionalities capable of either ( 1 ) linking to another monomer in an inter- or intramolecular fashion; (2) being immobilized on the solid suppon, or (3) attaching to other amino acids or peptides. Each monomer also contains an optional linking group binding site (X| or X2) that can be employed to link the monomers together in an intramolecular fashion. Furthermore, any or all of the base monomer structures, the terminal functionalities, and the linking group binding sites may contain reactive sites available for further diversification, as is discussed in more detail below.
As will be appreciated by those of ordinary skill in the art, a wide variety of first and second terminal functionalities may be employed lrf accordance with the present invention. As will also be appreciated, the selection of these functionalities for each monomer will depend on the nature of the moiety with which each functionality is to react. Terminal functionalities that may be employed include but are not limited to amines, CHrboxylic acids, halogenated aromatics for transition metal catalyzed cross coupling reactions, terminal aldehydes for pinacol couplings, terminal alkynes for hydrozirconation, arid terminal alkenes for olefin metathesis and nucleophilic addition. Figures 4, 5, 6, 7, 8 and 9 show the preferred cross-coupling, pinacol coupling, tandem aldol/Curtius rearrangement, hydrozirconization, nucleophilic addition, and NH (Nozaki-Hiyama-Kishi Furstner et al., J. Am. Chem. Sac. 1996, 118, 12349)) coupling, respectively.
In one particularly preferred embodiment, the second terminal functionality (LiZ) of the first monomer and the first terminal functionality (L21) of the second monomer are each alkenes, selected to be capable of reacting with one another. In another particularly preferred embodiment, one or both of the first terminal functionality (Lu) of the first monomer and the second terminal functionality (L22) of the second monomer is either an amine or carboxylic acid capable of further reacting with amino acids. In yet another preferred embodiment, at least one of the first terminal functionality (Ln) of the first monomer and the second terminal functionality (L22) of the second monomer is selected for linkage to a solid phase resin. Scheme 10 depicts the attachment of the diversifiable peptidomimetic structure of the present invention to the resin.
Those of ordinary skill in the art will appreciate that any of a variety of linking 13 group binding sites may be employed in accordance with the present invention, so long as the binding site can be reacted with a linking reagent to add a linking group to the monomer. The linking group then reacts to link the first and second monomers to one another.
Representative linking reagents include suifonyl chloride, dimethyl dichlorosilane, diisopropylamino chlorophosphoramidite and metais (such as boron and titanium) that are capable of temporary binding as a linker. One of ordinary skill in the art will realize that other linking reagents can be employed to generate mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides as linking groups.
Linking group binding sites can include any functionality capable of reaction with the selected linking reagent. Preferably, the linking group binding site comprises a carbon, oxygen, nitrogen, or sulfur atom, for example a hydroxyl, amino, or thiol group, through which the linking group becomes attached to the monomer. Scheme 2. below, depicts one particular preferred embodiment of a monomer for use in the present invention, in which L, , and L preferably each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, aikyne, amine, carboxylic acid, hdlogenated aromatic, aldehyde and vinyl halide; R,, R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, preferably comprises a functionality containing nitrogen, oxygen, sulfur or carbon; and L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent. 14 SUBSTITUTE SHEET (RULE 25) Scheme 2 Scheme 3 depicts the first monomer of Scheme 2 after linkage to a second monomer. In a panicularly preferred embodiment, the two monomers connected by the linking group are in a syi> relationship to each other. Preferably L- , Ln, L21, and L?2 each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; R1: R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, ary!, phenoxy, methoxy, halide, methylene cyciohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X3 and X.i each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon; and L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent. As will be appreciated by one of ordinary skill in the art, these monomers can be attached to a solid support unit, or may also be attached to a biomolecule or a polymer. The further treatment of such linked monomers is discussed more in detail below.
Scheme 3 In one particularly preferred embodiment of the present invention, the first and 5 second monomers are structurally related to one another so that the second monomer can be produced by chemical conversion of the first. For example, Figures 1 1 , 12 and 13 depict preferred embodiments of the present invention in which first and second monomers (depicted as C-terminal and N-terminal monomers, respectively) are synthesized convergently using known Evans' aldol chemistry (Evans et aL Am. Cham. Soc. 1982, i O 104. 1737).
These particular monomers are especially useful because they can be obtained in high yield. Furthermore, the monomer is capable of extensive diversification. For example, R can be. but is not limited to, methyl, ethyl, n-propyl, iso-propyl, cyciopentyl, phenoxy, methoxy, bromide, and methylene cyclohexyl, benzyl, chloride, carboxyalkyl, 15 carboxvaryl, arylalkyl, thio, hydroxyl, and heteroaryl functionalities. One of ordinary skill in the art will realize that the diversification is only limited by the compatibility of the particular functionality with subsequent chemical reactions.
Another important aspect of the monomers utilized in the present invention includes the ability to produce both syn and ami products. Specifically, Examples 1- 12 present the 20 synthesis of syn products, and examples 13- 19 present the synthesis of anti products.
Yet another important aspect of the particular monomers produced according to Figures 1 1 and 12 is their ability to be converted into useful second monomers by utilizing the Curtius rearrangement as shown below in Figures 12 and 13. The Curtius rearrangement yields a stereochemically pure second monomer from the first monomer and 16 thus under these reaction conditions, the stereocenters are rigidly set. In addition, stereochemical^ pure monomers can be obtained from other rearrangements such as the Hofmann. Lossen and Schmidt Rearrangements, as shown generally in Figure 14. The capability of controlling the stereochemistry of the present invention allows the development of peptidomimetics or libraries of peptidomimetics that may have certain desired conformational and binding properties.
Reading the Monomers Once appropriate monomers are selected to have the desired structural and reactive characteristics discussed above, a first monomer may be reacted with a second monomer, or a sole monomer may be diversified. In multiple monomer embodiments, the reaction of the first and second monomers may occur inter-or intramolecularly. That is, if the monomers have already been linked to one another as described above (see for example, Scheme 3), their subsequent reaction is intramolecular; if they have not been so linked, their reaction is intermolecular. Whether the reaction employed is intermolecular or intramolecular, the monomers are selected to have terminal functional moieties La and , capable of reaction with one another so that the monomers become attached. In particularly preferred embodiments of the invention, L,2 and L,, are both terminal alkenes. Alternatively, each of L,2 and L2, may be selected from the group comprising but not limited to alkenes, alkynes, amines, carboxylic acids, halogenated aromatics, aldehydes, and vinyl halides.
In an intramolecular reaction according to the present invention, the first and second monomers (depicted as C-terminal and N-terminal monomers, respectively) each have a linking group binding site and are linked together by means of a crosslinking reagent as shown in Figure 15. In a particularly preferred embodiment of the present invention, the first and second monomers each have a heteroatom-containing linking group binding site and are linked together by means of a silicon crosslinker such as dimethy!dichlorosilane as shown in Figure 16. In another particularly preferred embodiment of the invention, the monomers each contain a hydroxyl or amine linking group binding site and dusopropylamino chlorophosphoramidite is utilized as a linking reagent as shown in Figure 17 1 7. It is particularly preferred that these linked monomers comprise alkene terminal reactive moieties and thus are subjected to reaction conditions to effect an intramolecular metathesis reaction to generate an alkene moiety. One particular advantage of this approach is that the resultant linker provides a phosphorous moiety that can act as an additional site for functionalization. For example, oxidation can be employed to generate an oxide, which will enable further diversification. Additionally, the generation of a phosphate is advantageous because phosphorylation of peptides is a key step in many intracellular processes, and therefore peptidomimetic structures containing a phosphate-like moiety might be expected to interact with signaling proteins. Other preferred linking reagents include, but are not limited to sulfonyl chloride^and suitable reagents containing metals such as boron or titanium (e.g., TiCl ) One example of a preferred inventive intermolecular reaction is depicted in Figure 18, in which an olefin metathesis reaction yields two potential libraries. Olefin metathesis is effected by using transition metal catalysts for ring closing metathesis reactions.
Traditional ly, Grubbs' catalyst has been utilized for these types of reactions, however, recently, more efficient versions of this catalyst have been developed (see. Tel. Lett. , 1999, 40, 2247) to effect ring closing metathesis reactions for more difficult substrates. The mixture of compounds obtained from the non-hydrogenated product can be separated by subsequent deprotection and cyclization, for example as shown in Figure 19. Preferred intermolecular embodiments of the present invention also include linking the first and second monomers in a transition metal mediated crosscoupling reaction, such as the palladium catalyzed Heck Reaction as shown in Scheme 4, in which a haloaromatic first monomer is reacted with a second monomer under palladium (0) catalysis to yield an aromatic backbone and olefin that can be further functionalized. Furthermore, the amine functionality can also be deprotected and peptide coupling continued.
Preferred intermolecular embodiments of the present invention also include a pinacol coupling followed by elimination to yield an alkene, bond construction through tandem aldol reaction followed by Curtius rearrangement, hydrozirconization of terminal alkynes, and nucleophilic addition involving terminal alkenes, and NHK coupling, as shown in Figures 5, 6, 7, 8, and 9 respectively. 18 In preferred single-monomer embodiments of the present invention, the first monomer, instead of being reacted with a second monomer as described above, is reacted with a reactive moiety to yield a molecule containing a diversifiable segment unit and diversifiable functional groups (R). For example, a diastereoselective cycloaddition, based upon the work of Carreira et al. (J. Am. Chem. Soc. 1997, 119, 8379), is shown in Figure 20, in which dipolarophiies are reacted with Me3SiCHN, to yield A2-pyazotines. Each of the structures shown in Figure 20 contain reactive moieties which may be further functionalized. Alternatively, these reactive moieties are capable of attachment of biomolecules, preferably peptides, to yield complex compounds and libraries of compounds. Additionally, work from the thesis of Ann. Weber is shown in Figure 21 in which a diversifiable monomer is generated which contains four points of diversity. This moiety is also capable of attachment of biomolecules, such as peptides, to yield complex compounds and libraries of compounds.
Diversification and Combinatorial Sy thesis As discussed above, the present invention provides a system for the production of diverse, complex peptidomimetic and/or stereodiverse libraries. As already noted, each of the monomers utilized in the invention is capable of functional ization at one or more sites. That is, each monomer may contain functionaiizabie moieties as pan of the base monomer structure, the terminal functionalities, and the linking group binding site. Where the monomers are linked together prior to attachment through an intramolecular reaction, the linking reagents and therefore the linker attaching the monomers, may also contain one or more functionaiizabie sites. These functionaiizabie sites may be diversified with any desirable moiety, including but not limited to hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio, and hydroxyl. This functionalization, however, is in general limited to those functionalities that will not participate in undesirable side reactions during the coupling reaction. For example, olefins, more particularly terminal olefins, interfere with the coupling process because of their ability to participate in undesirable side reactions. Those of ordinary skill in the art will appreciate that monomers and/or linking 19 reagents can be functionalized either before or after being reacted, and thus the chemistry employed must be compatible with existing functionalities. Preferably, the monomers are first reacted to produce a single core molecule that is subsequently functionalized and diversified. The diversification reactions are preferably performed according to combinatorial approaches such as split-and-pooi or parallel synthesis. Preferably, the reactions are performed to produce libraries having at least approximately 10 members, more preferab ly at least approximately 1 ,000 members, and most preferably 10,000 to about 1 ,000,000 or about 10,000,000 members.
Scheme 4 represents one particular embodiment of a core molecule available for functionalization according to the present invention.
Scheme 4 Preferably Ln and L:: each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde and vinyl halide; R,, R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyl, thio and hydroxyl; X, and X each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon; L preferably comprises a group, including but not limited to mixed carbonates (R and R'), carbamates, disulfides, ureas, acetais, ortho esters, phosphates and oxides, produced by reaction with a linking reagent. In this embodiment, the core SUBSTITUTE SHEET (RULE 2B) functionality A is most preferably an alkene. It is well known that (E) olefin isoteres have been shown to be useful replacements for the amide linkage in drug candidates because the (E)-CR=CH group closely approximates the bond lengths, angles, and rigidities of the natural parent amide. However, as discussed above, the ability to generate compounds that do not necessarily mimic the structural properties of peptides, such as the (Z) olefin generated in the present system, constitutes an additional advantage of the present invention because it permits further investigation into unknown interactions between molecules and cellular receptors.
The structure depicted in Scheme 4 is available for randomization and diversification at several sites, allowing for the rapid syflthesis of a library of compounds capable of emulating peptidic functions and structures, although these compounds are not necessarily required to emulate peptidic structure. For example, diversification can be achieved through functionalization at the R groups, represented by R,, R2 and R3 as shown in Scheme 4. At such sites, various functionalities can be substituted including but not limited to hydrogen, alky , aryi, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, carboxyl, carboxalkyl, carboxaryl, arylalky!, thio, and hydroxyl.
Alternatively or additionally, the segment unit replacement, represented by A, may be diversified. For example, instead of utilizing olefin metathesis to yield a double bond motif, a 2 + 2 addition to yield a cyclobutane segment unit can be initiated by photolysis (Figure 21 ) or by the use of certain transition metal catalysts such as Ti(CH Ph)4. This segment unit can then be further diversified by cyclobutane ring opening reactions including but not limited to reactions with cuprates, radical type fragmentations and DeMayo fragmentations. Alternatively, the double bond product can be converted into a cyclopropane (Figure 23) which also can be further diversified by reaction with a variety of nucleophiles, such as cuprates or organometallics. Additional diversification of the double bond may be achieved by hydrogenation, epoxidation, or dihydroxylation.
Although Scheme 4 depicts linked monomers, one of ordinary skill in the an will realize that the present discussion of the diversification of A can be extended to other embodiments where the monomers are reacted intermolecularly. In such embodiments, the diversification of the segment unit A is achieved through palladium coupling reactions 21 (Figure 4), Pinacoi couplings (Figure 5), tandem aldol reactions/Curtius rearrangements (Figure 6) hydrozirconations (Figure 7), nucleophilic additions (Figure 8), and NFQ couplings (Figure 9). The segment unit A also includes but is not limited to cyclobutane, cyclopropane, alkene, alkane, heteroatom, alkyne and aromatic functionalities.
In another preferred embodiment of the present invention, the linking group can be removed to yield further diversifiable functionalities X, and X2, as shown in Scheme 5. These linking groups are preferably carbon, oxygen, sulfur or nitrogen containing functionalities such as hydroxy, thiol, or amine functionalities, which are capable of funher reaction with electrophiles. In one example, the hydroxyl group depicted in Figure 24 is selectively protected via the Hoffman Rearrangement. ''Preferably Lu and each comprise the same or different terminal reactive moiety selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxyiic acid, halogenated aromatic, aldehyde and vinyl halide, R,, R2 and R3 are preferably selected from the group consisting of hydrogen, alkyl, aryl, phenoxy, methoxy, halide, methylene cyclohexyl, benzyl, heteroaryl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, arylalkyi, thio and hydroxyl; X, and X4 each preferably comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; and X, and X2 preferably each comprise a functionality containing nitrogen, oxygen, sulfur or carbon. In this embodiment, the core functionality A is most preferably an alkene.
Scheme 5 22 Combinatorial Methods As mentioned above, the monomers may be diversified prior to or after reaction to generate core structures. Additionally, after their synthesis, the core structures can also be diversified. As will be appreciated by one of ordinary skill in the an, the synthesis of libraries from the above-described core structures and monomers can be performed using established combinatorial methods for solution phase, solid phase, or a combination of solution phase and solid phase synthesis techniques. The synthesis of combinatorial libraries is well known in the art and has been reviewed (see, e.g., "'Combinatorial Chemistry", Chemical and Engineering News, Feb. 24, 1997, p. 43; Thompson, L.A., Ellman, J . A.. Chem. Rev. 1996, 96, 555. ) One of ordinary skill in the art will realize that the choice of method will depend upon the specific number of compounds to be synthesized, the specific reaction chemistry, and the availability of specific instrumentation, such as robotic instrumentation for the preparation and analysis of the inventive libraries. In particularly preferred embodiments, the reactions to be performed on the monomers and core structures to generate the libraries are selected for their ability to proceed in high yield, and in a stereoselective fashion.
In one embodiment of the present invention, the inventive libraries are generated using a solution phase technique. Traditional advantages of solution phase techniques for the synthesis of combinatorial libraries include the availability of a much wider range of organic reactions, and the relative ease with which products can be characterized. Notable disadvantages of solution phase techniques includes the inability to easily synthesize libraries of compounds containing very large numbers, such as one million or more library members, because one reaction vessel must be provided for each library member, and the inability to use excess reagents without time-consuming purification steps, such as chromatography. Recently, however, advances have been made in solution phase synthesis techniques such as the use of a "covalent scavenger" which selectively removes from solution via covalent bond formation. The "covalent scavenger" is essentially a solid phase bound nucleophile or electrophile that reacts with these excess reagents. (Kaldor, Eli Lilly, Frechet et al., Tetrahedron Lett., 21 , 61 7 ( 1980)). In a preferred embodiment, for the generation of a solution phase combinatorial library, a parallel synthesis technique is 23 SUBSTITUTE SHEET (RULE 25) utilized, in which all of the products are assembled separately in their own reaction vessels. In a particularly preferred parallel synthesis procedure, a microtitre plate containing n rows and m columns of tiny wells which are capable of holding a few milliliters of the solvent in which the reaction will occur, is utilized. It is possible to then use n variants of reactant A, such as a carboxylic acid, and m variants of reactant B, such as an amide to obtain n x m variants, in n x m wells. One of ordinary .skill in the art will realize that this particular procedure is most useful when smaller libraries are desired, and the specific wells can provide a ready means to identify the library members in a particular well.
In another more particularly preferred embodiment of the present invention, a solid phase synthesis technique is utilized, in which the desiied scaffold structures are attached to the solid phase directly or though a linking unit, as discussed above. Advantages of solid phase techniques include the ability to more easily conduct multi-step reactions and the ability to drive reactions to completion because excess reagents can be utilized and the unreacted reagent washed away. Perhaps one of the most significant advantages of solid phase synthesis is the ability to use a technique called "split and pool", in addition to the parallel synthesis technique, developed by Furka. (Furka et al ., Absir. Nth Int. C ngr. Biochem., Prague, Czechoslovakia, 1988, 5. 47, Furka et al., Int. J. Pept. Protein Res. 1991. 3 ~. 487; Sebestyen et al., Bioorg. Med Chem. Lett. , 1993, 3, 413. ) In this technique, a mixture of related compounds can be made in the same reaction vessel, thus substantially reducing the number of containers required for the synthesis of very large libraries, such as those containing as many as or more than one million library members. As an example, the core structures or monomers can be divided into n vessels, where n represents the number species of reagent A to be reacted with the core structures or monomers After reaction, the contents from n vessels are combined and then split into m vessels, where m represents the number of species of reagent B to be reacted with the core structures or monomers. This procedure is repeated until the desired number of reagents is reacted with the core structures or monomers to yield the inventive library.
The use of solid phase techniques in the present invention may also include the use of a specific encoding technique. Specific encoding techniques have been reviewed by Czamik. (Czarnik, A.W., Current Opinion in Chemical Biology, 1997, /, 60.) As used in 24 the present invention, an encoding technique involves the use of a particular " identifying agenf attached to the solid support, which enables the determination of the structure of a specific library member without reference to its spatial coordinates. One of ordinary skill in the art will also realize that if smaller solid phase libraries are generated in specific reaction wells, such as 96 well plates, or on plastic pins, the reaction history of these library members may also be identified by their spatial coordinates in the particular plate, and thus are spatially encoded. It is most preferred, however for large combinatorial libraries, to use an alternative encoding technique to record the specific reaction history.
Examples of particular preferred alternative encoding techniques that can be utilized in the present invention include, but are not limited to, spatial encoding techniques, graphical encoding techniques, including the "tea bag" method, chemical encoding methods, and spectrophotometnc encoding methods. Spatial encoding refers to recording a reaction 's history based on its location. Graphical encoding techniques involve the coding of each synthesis platform to permit the generation of a relational database. Examples of preferred spectrophotometnc encoding methods include the use of mass spectroscopy, fluorescence emission, and nuclear magnetic resonance spectroscopy. In a most preferred embodiment, chemical encoding methods are utilized, which uses the structure of the reaction product to code for its identity. Decoding using this method can be performed on the solid phase or off of the solid phase. One of ordinary skill in the art will realize that the particular encoding method to be used in the present invention must be selected based upon the number of library members desired, and the reaction chemistry employed.
Peptide Morphing As mentioned above, one particular aspect of the present invention is the provision of methods and reagents for preparing and identifying chemical compounds that mimic certain desired structural and/or functional properties of a predetermined peptide. For example, a variety of techniques (e.g., alanine scanning mutagenesis, NMR, X-ray crystallography, etc.) are available for defining within a biologically active protein particular peptide sequences, or dispersed amino acids or small collections of amino acids, that are responsible for part or ail of the protein's function. Once such an active sequence is defined, the present invention provides a novel approach for preparing a non-peptide compound that captures the functionality of that sequence.
In particular, the methods discussed above provide libraries of chemical compounds that typically resemble of di- or tri-peptide moieties. As discussed above, the libraries can be prepared in the context of an existing peptide structure, that functions as a biasing element for the library, or can be embedded within a peptide after their preparation.
Thus, the techniques described herein allow preparation of a library of peptide derivatives corresponding to a known active sequence except that two or three residues of the sequence are replaced with an inventive library. This peptide derivative library can readily be screened to identify those compounds within it that retain the peptide activity of interest In this way, a portion of the peptide is "morphed" into another compound that retains the peptide activity.
This morphing method is not limited to substitution of a single di- or tri-peptide unit within an active sequence. Once one unit has been morphed, a second unit within the peptide can be subjected to the same procedure, and so on. Alternatively, two or more units may be morphed simultaneously. As yet another alternative, two or more units may be morphed in parallel and the final morphed structures may subsequently be embedded within a single peptide.
Once a portion of an active sequence has been successfully morphed, it may be possible to remove some or all remaining peptide sequence without destroying the peptide-like activity of the compound. Another way of removing all peptide components from an active sequence, of course, is to morph the entire sequence.
Uses The method, compounds, and libraries of the present invention can be utilized in various disciplines. Any available method may be employed to screen the libraries produced according to the present invention to identify those with desirable characteristics for a selected application. 26 To give just a few examples, the present invention can be utilized to produce peptidomimetic compounds that control (i.e., promote or inhibit) cell functions. Such compounds may be formulated and utilized as therapeutic pharmaceuticals. For example, such therapeutic pharmaceuticals, through interactions with cellular receptors, can control HIV production, cell proliferation, viral replication, gene expression, or any other cell signaling process. For example, a morphed segment produced according to the present invention can be embedded in a SH2 binding peptide, as shown in Figure 25. Figure 26 depicts model studies showing the binding of a morphed peptide to a SH2 domain. In another example, a library of inhibitors of DNA Glycosylases as shown in Figure 27 can be synthesized according to the method of the present invention. Additionally, a library of synthetic transcriptional regulators can be developed by the attachment of FK506 to the resi linked library of the present invention via an olefin linker as depicted in Figure 28. Furthermore, Figure 29 depicts a use for the inventive compounds and libraries in the E6 Έ6-ΑΡ system. Figure 30 depicts a use for the inventive compounds and libraries in the renin-angiotensin system. Finally, Figure 3 1 depicts a use for the inventive compounds and libraries as inhibitors of the proteasome.
Inventive peptidomimetic or stereodiverse compounds can alternatively or additionally be used for catalysis, either as a ligand for a transition metal capable of mimicking an important biological environment, or by acting in concert with a particular transition metal catalyst to effect a particular desired enantioselective chemical reaction.
Inventive peptidomimetic or stereodiverse compounds are also useful in the area of materials science. Because of the reactive moieties present at the terminal ends of these compounds, molecules such as lipids and other polymeric molecules may be attached and thus generate potentially important biomaterials.
It will be appreciated by one of ordinary skill in the art that the present invention is not intended to be limited to the abovementioned uses, but rather may be employed in many contexts and disciplines.
Examples 27 Example 1 : Norephedrine (compound 1) was purchased from Aldrich (28,255-3, 3 1 ,750-0, both enantiomers available) and used as received. Norephedrine (32 g, 21 1 mmoles) was placed in a flame-dried 250 ml round bottom flask equipped with a stir bar. Diethyl carbonate (60 ml, 422 mmoles) (Aldrich D9, 155- 1 ) and K2C03 (2.5 g, 21 mmoles) were added and the resulting slurry was heated to 120° C under a Dean-Stark trap for 16 hours. After that time, the reaction mixture was diluted with methylene chloride and water and extracted (3X) with 00 ml of methylene chloride, dried with anhydrous MgS04, filtered and concentrated under vacuum. Compound 2 was recrystallized from 1 :2 EtOAc/Hexanes. Yield: 34 g (91 %). ¾ Example 2: Compound 2 (8.9 g, 50 mmoles) was placed in a 500 ml round bottom flame-dried flask equipped with a stir bar and then dissolved in 150 ml THF. The solution was then cooled to -78 ° C and to this solution was added dropwise over a period of five minutes 1 .6 ml (50.5 mmoles) of 1 .6 M solution of n-BuLi in hexanes (Aldrich 18,617- 1 ). Upon complete addition, 4-methylvaJeroyl chloride (Pfaltz & Bauer M30370) was added via syringe. The solution was stirred at -78 "C for 30 minutes and then allowed to warm up to room temperature over 15 minutes. At this time, 100 ml of saturated NH4C1 was added. The organic solvent was removed under vacuum andthe remaining slurry was then extracted (3X) with 250 ml of methylene chloride, dried with anhydrous MgS04, filtered and concentrated under vacuum. Yield: 14.4 g ( 105%). Compound 3 was used in the next step without further purification.
Example 3: To a solution of compound 3 ( 15.4 g, 50 mmol) in 200 ml of methylene chloride cooled down to 0°C were added dropwise 55.0 ml of 1 .0 M solution of dibutylboron triflate in methylene chloride (Aldrich 26, 147-5) and redistilled diisopropy lamine ( 10.5 ml, 60 mmol) at a rate such that the internal temperature did not exceed 3.0°C. The resulting 28 clear, colorless solution was cooled down to -7S° C and acrolein ( 16.7 ml, 250 mmol, Aldrich 1 1 ,022- 1 ), dried by pouring through a short plug of neutral aluminum oxide immediately before use) was then added via syringe over a period of five minutes. After stirring for 60 minutes at -78 ° C, the reaction was quenched by adding 200 ml of 5 : 1 MeOH/H:02, which was precooled to 0° C, and stirred for another 10 minutes at -78 ° C and then 30 minutes at 0"C. The reaction volume was reduced by removing the organic solvents under vacuum, 300 ml of methylene chloride and 300 ml of 5% NaHC03 were added and the product was extracted (3X) with methylene chloride, dried with anhydrous gS04. filtered and concentrated under vacuum. Yield: 22.0 g ( 133 %). The crude compound 4 was used in the next step without further purification.
Example 4: in a flame-dried round bottom flask equipped with a stir bar, benzylmercaptane ( 1 1 .3 ml. 100 mmol, Aldrich B2,540- l ) was dissolved in 75 m l of THF and the solution was cooled to 0° C and 1 .6 M solution of n-BuLi in hexanes (62.5 ml, Aldrich 18,617- 1 ) was added dropwise over a period of five minutes. To that solution, 2.0 M solution of AlMe, in toluene (50.0 ml, Aldrich 1 ,804-8 ) was added dropwise over a period of five minutes. The reaction was allowed to stir for an additional 30 minutes at 0° C and the solution of BnSAlMe3Li was added dropwise via cannula. The reaction was stirred for 120 minutes at 0°C, carefully quenched with 200 ml of 1 .0 M aqueous solution of HC1 (vigorous foaming) at 0 °C and then stirred for an additional 30 minutes at room temperature. The reaction was extracted (3 X) with 200 ml of EtOAc, dried with anhydrous MgS04, filtered and concentrated under vacuum. Compounds 2 and 5 in the crude reaction mixture were separated by precipitating compound 13 from neat hexanes. The hexane solution of compound 5 was concentrated under vacuum and purified by flash chromatography in 7: 1 Hexanes EtOAc + 0.2% eOH. Yield: 8.0 g (58 % over the last three steps). Compound 2 was recrystallized from 1 :2 hexanes/EtO Ac. Yield: 6. 1 g (68%). 29 Example 5: In a 25 ml flame-dried round-bottom flask equipped with a stir bar. compound 5 (4.50 g, 16 mmol) was dissolved in 4.0 ml of DMF and to this solution was added TBD SC1 (3.0 g, 20 mmoles, Aidrich 19,050-0) and imidazole (2.2 g, 32 mmoles, Aldrich 43,61 5- 1 ). The reaction was allowed to stir for 14 hours at room temperature. After this time, the reaction was quenched by the addition of 30 ml of saturated aqueous NaHC03 and extracted (3X) with methylene chloride, dried with anhydrous gS04, filtered and concentrated under vacuum . Yield: 6.9 g ( 1 10%). Compound 6 was used in the subsequent step without further purification. * Example 6: in a 500 ml round-bottom flask equipped with a stir bar, compound 6 (5. 1 g, 13 mmoles) was dissolved in 160 ml of THF, 50 mi of eOH and 50 ml H20. The solution was cooled down to 0° C and 1.2 g of LiOH and 9.0 ml of 30 % Β,Ο, was added, respectively. The reaction was allowed to warm up to room temperature and, after 8 hours at room temperature, it was quenched by addition of 1 .0 aqueous solution of Na2SO , ( 156 ml, Aldrich 20,784-5) at 0° C and stirred at room temperature for an additional 30 minutes. The reaction was acidified to pH = 2 by adding 200 ml of 1.0 M KHS04 (pH of the aqueous layer was checked by using pH paper strips). The reaction was extracted (3 X) with methylene chloride, dried with anhydrous MgSO^, filtered and concentrated under vacuum. Yield: 4.8 g ( 105 %). Compound 7 was used in the subsequent step without further purification.
Example 7: REFERENCE: Synthesis 131 , ( 1989) In a 250ml flame-dried round-bottom flask equipped with a stir bar, compound 7 (4.8g, 16mmoles) was dissolved in 80 ml of distilled acetonitrile. To this solution, freshly distilled TEA (2.5ml, 1 8 mmoles) was added followed by diphenylphosphoryl azide (3.8ml, \ 8 mmoles, Aldrich 17,875-6). A condenser was placed on the flask and the reaction was refluxed for 30 minutes at 85 °C. The reaction was then cooled to room temperature and CuCl (0.4g, 4 mmoles, Aldrich 22,962-8) was added followed by 9-fluorenemethanol (9.4g, 48 mmoles, Aldrich 16,050-4) The reaction was stirred for additional 120 minutes at room temperature and quenched by addition of 100 ml of saturated NaHC03. The reaction was extracted (3X) with EtOAc, dried with anhydrous MgS04> filtered and concentrated under vacuum. The crude product was purified by flash chromatography ( 19: 1 hexanes/EtOAc +0.2%MeOH). Yield: 3.6g (47%).
* Example 8: REFERENCE: J ACS 94, 6195, ( 1 972) In a 250ml round-bottom flask equipped with a stir bar, compound 8 (3.6g, 7.5 mmoles) was dissolved in 45 ml of AcOH, 1 5 ml of H20 and 1 5 m l of THF and stirred at 45°C for 4 hi s. After that time, the solvent was removed under vacuum by azeotropic distillation with toluene and the crude product was purified by flash chromatography (4: 1 Hexanes^tOAc+0.2%MeOH). Yield: 2.0 g (73%).
Example 9 REFERENCE: JACS 1 13, 9661, ( 1991 ) A 25ml flame-dried round bottom flask was charged with freshly distilled dimethyldichlorosilane (2.4 ml, 20 mmoles, Aldrich 44,027-2) and 5 ml of freshly distilled pyridine were added. In a separate flask, compound 5 (278 mg, 1 mmole) was dissolved in 2.0 ml of freshly distilled pyridine and transferred via cannula to the solution of dimethyldichlorosilane in pyridine. The flask was then washed with another 0.5 ml of pyridine and the reaction was stirred for 2 hrs at room temperature. After that time, a short-path distillation head was placed on the flask and excess dichlorodimethylsilane and pyridine were removed under high vacuum. To the resulting slurry, compound 9 (365 mg, Immole) dissolved in a separate flask in 9 ml of freshly distilled pyridine was transferred 3 1 via cannula and the reaction was stirred for another 2 hours at room temperature. The excess of pyridine was removed under high vacuum, 20 ml of saturated NaHC03 were added and the reaction was extracted (3X) with EtOAc, dried with anhydrous MgS04, filtered and concentrated under vacuum. The crude product was purified by flash chromatography ( 15: 1 hexanes/EtOAc+0.2%MeOH). Yield: 427 mg (61%).
Example 10: A 25 ml flame-dried round-bottom flask was charged with compound 1 1 (427 mg, 0.61 mmoles) and 6 ml of distilled THF were added. A reflux condenser was placed on the flask and the system was flushed with argon. In a separate flask, the Grubbs' catalyst (255 mg, 0.3 1 mmoles, Strem 44-0065) was dissolved in 3.0 ml of freshly distilled methylene chloride and transferred via cannula to the flask containing compound 12 which was then heated to 40° for 24 hours. After that time, another portion of the Grubbs' catalyst (255 mg, 0. 1 mmoles dissolved in 3.0 ml of freshly distilled dichloromethane) was added via cannula and the heating was continued for another 24 hours. The reaction was then concentrated under vacuum and purified by flash chromatography ( 12 : 1 hexanes/EtOAc+0.2% eOH). Yield: 1 16 mg (28%), recovered starting material: 185 mg (43%). The recovered starting material was resubjected to the same metathesis conditions with the same percentage yield of the product. Additionally, this metathesis reaction can be now carried out with 5% mol percent of the new catalyst (Grubbs et al.. Tel. Lett. , 1999, 40, 2247; Nolan et al., accepted for publication in J. Am. Chem. Soc ). This improved catalyst greatly increases the efficiency of the metathesis reaction.
Example 11 : In a 50 ml Corning plastic test tube, compound 11 ( 166 mg, 0.25 mmoles) was dissolved in 1 ml of THF and cooled down to 0°C. A solution of HF in pyridine (71 ml, 2.5 mmoles, Aldrich 18,422-5) was added dropwise, the reaction was allowed to warm up to room temperature and stirred for additional 30 minutes at room temperature. After that time, the reaction was carefully quenched with 10 ml of 1 .0M Na2C03 (vigorous foaming), O 99/48897 extracted (3 X) with EtOAc, dried with anhydrous gS04, filtered and concentrated under vacuum. The crude product was purified by flash chromatography (3 : 1 hexanes/TEtOAc+ 1.0 eOH). Yield: 85 mg (50%). Note: The low yield is most likely caused by the residual catalyst decomposition products increasing the weight of compound 11 before the deprotection.
Example 12: In a 5 ml flame-dried pear-shaped flask, compound 12 ( 106 mg, 0. 13 mmoies) was dissolved in 1.3 ml of THF. To that solution, DIPEA (46 ml, 0.26 mmoies) and Hg(OCOCF3)2 ( 1 1 1 mg, 0.26 mmoies, Aldrich 15,648-5) were added, respectively and the resulting yellow solution was stirred for another 30 minutes at room temperature. After that time, the reaction was concentrated under vacuum and the crude product (compound 13) purified by flash chromatography ( 1 : 1 hexanes/EtOAc÷ 1.0%MeOH). Yield : 55 mg (65%).
Exampte 13: REFERENCE: JACS ( 1997), 119, 2586 Norephedrine (compound 1 ) was purchased from Aldrich (28,255-3, 3 1 ,750-0, both enantiomers available) and used as received. Norephedrine (7.6g, 50 mmoies) was placed in a flame-dried 500mi round-bottom flask equipped with a stir bar, dissolved in 200 ml of freshly distilled methylene chloride and cooled down to 0°C. Freshly distilled Et3N (8.3 ml, 60 mmoies) was added slowly over a period of 5 minutes and then 2-mesitylenesu fonyl chloride (Aldrich 770-7, 1 1.0 g, 50 mmoies) dissolved in 25 ml of freshly distilled methylene chloride was added slowly via cannula over a period of 5 minutes. The reaction mixture was allowed to warm to room temperature and stirred for another 4 hours. After that time, the reaction mixture was extracted (3X) with EtOAc, dried with anhydrous MgS0 , filtered and concentrated under vacuum. The crude product (compound 14) was recrystallized from methylene chloride:hexane. Yield: 15.7 g (94%).
Example 14: REFERENCE: JACS ( 1997), 1 19, 2586 Compound 14 ( 15.7g, 47 mmoles) was placed in a 500ml round-bottom flame-dried flask equipped with a stir bar and then dissolved in 1 88 ml freshly distilled acetonitrile. To that solution, K2C03 (9.7 g, 71 mmoles) and benzyl bromide (Aldrich B l , 790-5, 6.8 ml, 56 mmoles) were added, respectively. The flask was equipped with a reflux condenser and refluxed for 36 hours. After that time, the reaction was quenched with 20 ml of saturated NH C1, extracted (3X) with EtOAc, dried with anhydrous MgS04, filtered and concentrated under vacuum. The crude product (compound 15)· was purified by flash chromatography (6: 1 -> 4: 1 hexanes:EtOAc + 0.2% MeOH gradient). Yield: 17.7 g (89%).
Example IS: REFERENCE: JACS ( 1997), 119, 2586 Compound 15 (4.2g, 10 mmoles) was placed in a 200ml round-bottom flame-dried flask equipped with a stir bar, dissolved in 43 ml of freshly distilled methylene chloride and cooled down to 0°C. Freshly distilled pyridine ( 1 . 1 ml, 13 mmoles) was dropwise and after 10 minutes 4-methylvaleroyl chloride (Pfaltz & Bauer 30370, 1.6 ml, 12 mmoles) was added dropwise via syringe. The reaction was allowed to warm to room temperature and stirred for another 16 hours. After that time, the reaction mixture was extracted (3X) with EtOAc, dried with anhydrous MgS04, filtered and concentrated under vacuum. The crude product (compound 16) was used in the subsequent step without further purification. Yield: 5.6 g ( 108%).
Example 16: REFERENCE: JACS ( 1997), 119, 2586 Compound 16 (5.6g, 10 mmoles) was placed in a 250ml round-bottom flame-dried flask equipped with a stir bar, dissolved in 75 ml of freshly distilled methylene chloride and cooled down to 0°C and freshly distilled Et3N was added via syringe. The reaction mixture 34 was cooled down to -78°C and a precooled 1.0 M solution of Cx:B0Tf in methylene chloride (20 ml, 20 mmoles - prepared as described in JOC ( 1992), 57, 499 and JOC ( 1993 ), 58, 147) was added slowly via cannula over a period of five minutes. The reaction was stirred for additional 2 hours at -78°C after which time acrolein (0.8 ml, 12 mmoles, Aldrich 1 1 ,022-1 , dried by pouring through a short plug of neutral aluminum oxide immediately before use) was added vi syringe and the reaction was stirred for another hour at -78°C and then for another hour at 0°C. After that time, the reaction was quenched by adding 40 ml of l'.OM phosphate buffer (pH=7.0), 100 ml of MeOH and 10 ml of 30%H2O2 and stirred for 1 hour at room temperature. The quenched reaction was extracted (3X) with methylene chloride, dried with anhydrous MgSO,,, filtered and concentrated under vacuum. The crude product (compound 17) was purified by flash chromatography in 6: 1 hexanes:EtOAc + 0.2 MeOH. Yield: 5.2 g (90%).
Example 17: REFERENCE: TL ( 1 86), 27, , 1735 Compound 17 (5.2 g, 9 mmoles) was placed in a 200 ml round-bottom flask and dissolved in 72 ml of methanol. To that solution, NaOH (1 .8 g, 45 mmoles) dissolved in 1 8 ml of water was added slowly and the resulting cloudy solution was stirred for additional 14 hours at room temperature. After that time, methanol was removed on rotatory evaporator, 200 ml of water was added to the resulting slurry and the clear solution was extracted (3X) with EtOAc. The organic layer was dried with anhydrous MgS04, filtered and concentrated under vacuum. The crude compound 15 was recrystallized from methylene chloride: hexane. Yield: 3.4 g (90%). The aqueous layer was acidified to pH=l by adding concentrated HC1 and extracted (3X) with EtOAc dried with anhydrous MgS04, filtered and concentrated under vacuum. Compound 18 was used in the subsequent step with further purification. Yield. 1.2 g (80%).
Example 18: Compound 18 ( 1 .2 g, 7 mmoles) was dissolved in 3 ml of freshly distilled 138647/2 WO 99/48897 PCT US99/06233 methylene chloride and benzylmercaptane (2.4 ml, 22 mrnoles, Aldrich B2.540- 1) was added. The solution was cooled down to 0°C and 1.0M solution of DCC in methylene chloride (7.9 ml, 7.9 mrnoles, Aldrich 37,91 1 -5) was added dropwise via syringe and stirred for another 5 minutes at 0°C. After that time, the reaction was warmed up to room temperature and stirred for additionai 2 hours. The reaction mixture was then diluted with EtjO, filtered through a short plug of Celite and concentrated under vacuum. The crude product (compound 19) was purified by flash chromatography in 8: 1 hexanes:£tOAc + 0.2 MeOH. Yield: 1 .5 g (75%). 11 All passages of the description, which are not within the scope of the claims, do m part of the invention. 36

Claims (23)

138647/4 CLAIMS:
1. A method for generating a library of compounds having stereochemical diversity comprising: selecting desired synthetic precursors having a defined stereochemical relationship; reacting the synthetic precursors under olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction conditions to yield one or more compounds having specific stereochemistry; repeating the steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained.
2. The method of claim 1 , wherein the step of selecting desired synthetic precursors having defined stereochemical relationships comprises selecting two monomers, each independently selected from a specific compound having the general structure: wherein Ln and L12 are each independently selected from the group consisting of hydrogen, protecting group, alkene, alkyne, amine, carboxylic acid, halogenated aromatic, aldehyde, vinyl halide, NHR1; SRl3 ORi, wherein each occurrence of Ri is independently selected from the group consisting of protected or unprotected, functionalized or unfunctionalized amino acid, functionalized or unfunctionalized peptide, functionalized or unfunctionalized peptide fragment, solid support unit, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit) and (functionalized or unfunctionalized peptide fragment-solid support unit); wherein X comprises a functional moiety selected from the group consisting of carboxyl, amino, gem-dialkyl, and methylene; wherein R is selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, C1-C4 alkyl, aryl, phenoxy, methoxy, halide, SMe, cycloalkyl, - 37 - 138647/3 (CH2)-cycloalkyl, benzyl, arloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; and wherein comprises a moiety selected from the group consisting of hydrogen, hydroxy, protected hydroxy, thiol, protected thiol, N3, amino, protected amino, alkylamino and dialkylamino, whereby each of said monomers may comprise the same or different specific compound; and wherein the step of reacting the synthetic precursors comprises linking said same or different monomers using a linking reagent and subsequently reacting said monomers intramolecularly.
3. The method of claim 2, wherein said monomers are reacted intramolecularly using olefin metathesis.
4. The method of claim 1 or claim 2 further comprising the step of diversifying said synthetic precursors after the step of selecting desired synthetic precursors so that a chemical library having stereochemical and structural diversity is obtained.
5. The method of claim 1 or claim 2, further comprising a step of diversifying said compounds having a specific stereochemistry after the step of reacting the synthetic precursors so that a chemical library having stereochemical and structural diversity is obtained.
6. A method for preparing a morphed peptide derivative, the method comprising the steps of: identifying an active peptide sequence; replacing at least one di- or tri-peptide unit, or at least one of both, with a non-peptide morphed unit synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and identifying a peptide derivative that retains at least part of the active sequence activity.
7. The method of claim 6, further comprising replacing at least one di- or tri-peptide unit, or both, with a selected stereoisomer of a non-peptide morphed unit.
8. A method for preparing a library of morphed peptide derivatives, the method comprising the steps of: identifying one or more biologically active peptide sequences; - 38 - 138647/3 replacing, in said one or more active peptide sequences, at least one di- or tri-peptide unit, or both, with a non-peptide unit synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and screening the peptide derivative library to identify one or more peptide derivatives within it that retain at least part of the active sequence activity.
9. The method of claim 8, further comprising replacing at least one di- or tri-peptide unit in said one or more biologically peptide sequences, with selected stereoisomers of one or more structural isomers of a non-peptide morphed unit.
10. A method for morphing a peptide into a non-peptide compound, the method comprising the steps of: identifying a biologically active peptide sequence; preparing a library of morphed peptides in which each peptide has the active sequence except that at least one di- or tri-peptide unit, or both, has been substituted with a library of non-peptide morphed units synthesized by olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction; and screening the peptide derivative library to identify one or more peptide derivatives within it that retain at least part of the active sequence's activity.
11. The method of claim 10, further comprising: preparing a second library of morphed peptide derivatives, the second library being produced from the first identified peptide derivative by substituting at least a second di- or tri-peptide moiety within the first derivative with a library of non-peptide morphed units; and screening the second peptide derivative library to identify one or more second peptide derivatives that retain at least part of the active sequence's activity.
12. The method of claim 11, wherein the steps of preparing and screening libraries are integrated until a compound including no peptide bonds, but retaining at least part of the active sequence's activity is produced.
13. The method of any one of claims 10 to 12, wherein said library of non-peptide morphed units substituted into a di-peptide or tri-peptide unit, or both, of the active peptide sequence comprises the structure: - 39 - 138647/4 wherein R and R2 are each independently selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, Ct-C4 alkyl, aryl, phenoxy, methoxy, halide, SMe, cycloalkyl, (CH2)-cycloalkyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; wherein A is absent, whereby -C(X2) form a covalent bond, or wherein A is selected from the group consisting of: alkane; -(CH2)n-(CH=CH)-, where n = 0 or 1 ; aryl; substituted aryl; heterocycle; substituted heterocycle; cycloalkane; substituted cycloalkane; and alkyne; wherein X\ and X2 are each independently selected from the group consisting of hydrogen, hydroxy, protected hydroxy, thiol, protected thiol, N3, amino, protected amino, alkylamino, and dialkylamino; and wherein (Ln-X) and (X4-L22) each taken together are each independently selected from the group consisting of: -CH2-NHR4; -COOR^ -CH2OR4; -COSRY4; -NH-CO-R4 wherein each occurrence of R4, as valency and stability permit, is independently selected from the group consisting of hydrogen, hydroxy, alkyl, protecting group, solid - 40 - 138647/4 support unit, functionalized or unfunctionalized, protected or unprotected peptide or fragment thereof, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit), and (functionalized or unfunctionalized peptide fragment-solid support unit); and [R2 and (¾-L22)] or [R and (X-Ln)] taken together each independently comprise a protecting group, or a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocyclic moiety.
14. The method of claim 13, wherein R and R2 are each independently selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, Ci-C4 alkyl, aryl, phenoxy, methoxy, halide, , cycloalkyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; wherein A is absent, whereby -C(X and -C(X2) form a covalent bond, or wherein A is selected from the group consisting of -(CH2)n-(CH=CH)-, where n = 0 or 1, alkane and cycloalkane; wherein Xj and X2 are each independently selected from the group consisting of hydrogen, hydroxy, protected hydroxy, amino, and protected amino, and wherein (X-Ln) and (X4-L22) each taken together are each independently NH j, -CO-NH-R4 or -NH-CO-R4, wherein each occurrence of R4 is independently selected from the group consisting of hydrogen, hydroxy, alkyl, protecting group, solid support unit, functionalized or unfunctionalized, protected or unprotected peptide or fragment thereof, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit, and (functionalized or unfunctionalized peptide fragment-solid support unit).
15. The method of any one of Claims 10 to 12, wherein said library of non-peptide morphed units substituted into a di- or tri-peptide of a biologically active peptide sequence comprises the structure: wherein L comprises a moiety selected from the group consisting of mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent; - 41 - 138647/4 wherein R\ and R2 are each independently selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, Ci-C4 alkyl, aryl, phenoxy, methoxy, halide, SMe, cycloalkyl, (CH2)-cycloalkyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; wherein A is absent, whereby -C(Xi) and -C(X2) form a covalent bond, or wherein A is selected from the group consisting of: alkane; -(CH2)n-(CH=CH)-, where n = 0 or 1 ; aryl; substituted aryl; heterocycle; substituted heterocycle; cycloalkane; substituted cycloalkane; and alkyne; wherein Xj and X2 are each independently selected from the group consisting of hydrogen, hydroxy, protected hydroxy, thiol, protected thiol, N3, amino, protected amino, alkylamino, and dialkylamino; and wherein (Ln-X) and (X4-L22) each taken together are each independently selected from the group consisting of: -NHR4; -CH2-NHR4; -COOR4; -CH2OR4; -COSRY4; -CO-NH-R4; - H-CO-R4 wherein each occurrence of R4, as valency and stability permit, is independently selected from the group consisting of hydrogen, hydroxy, alkyl, protecting group, solid support unit, functionalized or unfunctionalized, protected or unprotected peptide or fragment thereof, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit), and (functionalized or unfunctionalized peptide fragment-solid support unit); and - 42 - 138647/4 [R2 and (X4-L1 i)] or [Ri and (X3-Ln)] taken together each independently comprise a protecting group, or a substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocyclic moiety.
16. The method of claim 15, wherein L comprises a moiety selected from the group consisting of mixed carbonates (R and R'), carbamates, disulfides, ureas, acetals, ortho esters, phosphates and oxides, produced by reaction with a linking reagent; wherein Ri and R2 are each independently selected from the group consisting of hydrogen, amino acid side chains, protected amino acid side chains, Ci-C4 alkyl, aryl, phenoxy, methoxy, halide, SMe, cycloalkyl, benzyl, aryloxy, heteroaryl, carboxyl, carboxalkyl, carboxaryl, alkylaryl, thiol and hydroxyl; wherein A is absent, whereby -C(Xi) and -C(X2) form a covalent bond, or wherein A is selected from the group consisting of -(CH2)n -(CH=CH)-, where n = 0 or 1 , alkane and cycloalkane; wherein X\ and X2 are each independently selected from the group consisting of hydrogen, hydroxy, protected hydroxy, amino; and protected amino, and wherein (Χ-Ln) and (X4-L22) each taken together are each independently NHR4, -CO-NH-R4 or -NH-CO-Rt, wherein each occurrence of R4 is independently selected from the group consisting of hydrogen, hydroxy, alkyl, protecting group, solid support unit, functionalized or unfunctionalized, protected or unprotected peptide or fragment thereof, (functionalized or unfunctionalized amino acid-solid support unit), (functionalized or unfunctionalized peptide-solid support unit), and (functionalized or unfunctionalized peptide fragment-solid support unit).
17. A morphed peptide derivative prepared by a method according to claim 6 or claim 7.
18. A library of morphed peptide derivatives prepared by a method according to claim 6 or claim 7.
19. A non-peptide compound morphed by a method according to any one of claims 10 to 16.
20. A method for generating a library of compounds having stereochemical diversity according to claim 1 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
21. A method according to claim 6 or claim 7 and substantially as herein described with reference to any one of the examples but excluding comparative examples, wherein an olefin metathesis reaction, Pinacol coupling reaction, tandem Aldol/Curtius - 43 - 138647/3 rearrangement reaction, hydrozirconation reaction, or Nozaki-Hiyama-Kishi reaction is used.
22. A method according to claim 8 or claim 9 and substantially as herein described with reference to any one of the examples but excluding comparative examples.
23. A method according to any one of claims 10 to 16 and substantially as herein described with references to any one of the examples but excluding comparative examples. For the Applicants, - 44 -
IL138647A 1998-03-23 2000-09-22 Synthesis of compounds and libraries of compounds IL138647A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7903598P 1998-03-23 1998-03-23
PCT/US1999/006233 WO1999048897A2 (en) 1998-03-23 1999-03-22 Synthesis of compounds and libraries of compounds

Publications (1)

Publication Number Publication Date
IL138647A true IL138647A (en) 2006-10-31

Family

ID=22148010

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13864799A IL138647A0 (en) 1998-03-23 1999-03-22 Synthesis of compounds and libraries of compounds
IL138647A IL138647A (en) 1998-03-23 2000-09-22 Synthesis of compounds and libraries of compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13864799A IL138647A0 (en) 1998-03-23 1999-03-22 Synthesis of compounds and libraries of compounds

Country Status (6)

Country Link
EP (1) EP1066295A2 (en)
JP (1) JP2002507617A (en)
CA (1) CA2324016A1 (en)
HU (1) HUP0103260A3 (en)
IL (2) IL138647A0 (en)
WO (1) WO1999048897A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60127958D1 (en) * 2000-06-05 2007-05-31 Novartis Vaccines & Diagnostic MICROARRAYS FOR PERFORMING PROTEOMAL ANALYSIS
US7148058B2 (en) 2000-06-05 2006-12-12 Chiron Corporation Protein microarrays on mirrored surfaces for performing proteomic analyses
US7153682B2 (en) 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
JP3893030B2 (en) * 2001-04-18 2007-03-14 独立行政法人科学技術振興機構 Bacterial endotoxin adsorbent and screening method thereof
DE02800437T1 (en) 2001-10-03 2004-11-11 The President And Fellows Of Harvard College, Cambridge COPOLYMERS FOR SUPPRESSING AUTOIMMUNE DISEASES AND METHODS OF USE
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
AU2006216635B2 (en) 2005-02-25 2011-11-17 University Of Utah Research Foundation Tropoelastin for promoting endothelial cell adhesion or migration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
JP3394777B2 (en) * 1993-05-27 2003-04-07 セレクタイド コーポレーション Topologically separated, encoded solid-phase library
IL106106A0 (en) * 1993-06-22 1993-10-20 Interpharm Lab Ltd Library of polymeric molecules and its preparation
EP0904540A1 (en) * 1996-03-22 1999-03-31 Ontogen Corporation Methods for spatially-dispersed positionally-encoded combinatorial library synthesis
DE19619373A1 (en) * 1996-05-14 1997-11-20 Hoechst Ag New substance library and the resulting supramolecular complexes

Also Published As

Publication number Publication date
IL138647A0 (en) 2001-10-31
HUP0103260A3 (en) 2002-03-28
HUP0103260A2 (en) 2002-02-28
CA2324016A1 (en) 1999-09-30
WO1999048897A2 (en) 1999-09-30
JP2002507617A (en) 2002-03-12
EP1066295A2 (en) 2001-01-10
WO1999048897B1 (en) 2000-01-20
WO1999048897A3 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
US7183059B2 (en) Synthesis of compounds and libraries of compounds
Candeias et al. Boronic acids and esters in the Petasis-borono Mannich multicomponent reaction
US5939268A (en) Combinatorial libraries of molecules and methods for producing same
US8198218B2 (en) Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads
US6316616B1 (en) Parallel combinatorial approach to the discovery and optimization of catalysts and uses thereof
Gordon et al. Solid phase synthesis–designer linkers for combinatorial chemistry: a review
US7045360B2 (en) Method for analysis of reaction products
Chamakuri et al. Synthesis of enantiomerically pure 6-substituted-piperazine-2-acetic acid esters as intermediates for library production
CN107835871B (en) Methods and compositions for peptide cyclization and protease treatment
Shugrue et al. Divergent stereoselectivity in phosphothreonine (pThr)-catalyzed reductive aminations of 3-amidocyclohexanones
IL138647A (en) Synthesis of compounds and libraries of compounds
Romero-Estudillo et al. Domino process achieves site-selective peptide modification with high optical purity. Applications to chain diversification and peptide ligation
US7126006B2 (en) Glycoluril core molecules for combinatorial libraries
US20030082830A1 (en) Synthesis of combinatorial libraries of compounds reminiscent of natural products
Ganesan Integrating natural product synthesis and combinatorial chemistry
US20010024798A1 (en) Biomimetic combinatorial synthesis
WO2020220651A1 (en) Method for synthesizing chiral 2-hydroxy-1,4-dicarbonyl compound and pantolactone
US6388022B1 (en) Linker binding carriers for organic synthesis, their production and use
US6175020B1 (en) Spirodiamino acid scaffold for combinatorial synthesis
Li et al. Modular Synthesis of Enantioenriched α-Chiral Homoallylic Amidines Enabled by Relay Ir/Cu Catalysis
WO1998035923A1 (en) Process for creating molecular diversity
Krueger The development and application of new catalytic asymmetric reactions through diversity approaches
Chen Pin1 Catalytic and WW Domain Ligands
Haque et al. Bristol-Myers Squibb Company Wilmington, Delaware

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees